VEGFA and neoplasm: By blocking VEGF/VEGFR pathway, antiangiogenic inhibitors not only inhibits tumor growth, but also impairs the repair capacity of endothelial cells and causes defects of the plasma membrane or underlying matrix, thus resulting to an increased risk of hemorrhage/bleeding [16].